Belite Bio
Update in progressBLTE (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Belite Bio, Inc. is a San Diego-based clinical-stage biopharmaceutical company developing novel therapies for retinal degenerative diseases with unmet medical needs in the United States. Its lead candidate, Tinlarebant (LBS-008), is an oral therapy in phase 3 for early intervention to preserve retinal health in Stargardt disease type 1 and geographic atrophy. LBS-009 is a preclinical oral anti-RBP4 candidate targeting liver disease, NAFLD/NASH, type 2 diabetes, and gout. Founded in 2016, it is a subsidiary of Lin Bioscience International Ltd.
Company score
- Sentiment
- 0.41
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.29
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Yu-Hsin Lin M.B.A., Ph.D.
- Founded2016
- Employees41
- Websitewww.belitebio.com
Identifiers
- ISINUS07782B1044
- FIGIBBG016LJYT18
- CUSIP07782B104
- CIK0001889109